On January 19, 2023 Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing novel synthetic lethality-based cancer therapeutics targeting DNA damage response (DDR) pathways, reported that it will participate in the 6th Annual DDR Inhibitors Summit, held in Boston, Massachusetts from January 24 – January 26, 2023 (Press release, Aprea, JAN 19, 2023, View Source [SID1234626371]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Oren Gilad, Ph.D., President and Chief Executive Officer of Aprea, will participate in a panel discussion entitled "How Are Newer Targets Being Validated to Move Towards Clinical Trials?" and present in two sessions. In addition, Eric Brown, Ph.D., Scientific Consultant to Aprea and a member of the Scientific Advisory Board, will present on Repli-Biom, Aprea’s proprietary discovery platform of novel synthetic lethal targets and biomarkers.

Details for the panel and presentations are as follows:

Panel Discussion: How are Newer Targets Being Validated to Move Towards Clinical Trials?
Date & Time: Wednesday, January 25, 2023 at 5:30 pm ET
Session: Exploring Novel Targets on the Horizon & Discussing Their Potential as Monotherapy Agents
Presenter: Oren Gilad, Ph.D., President and Chief Executive Officer

Presentation: Understanding DDRi’s In the Clinic: Why is Toxicity Such a Big Issue?
Date & Time: Thursday, January 26, 2023 at 9:00 am ET
Session: Unpacking an Ongoing Clinical Challenge & DDR Inhibition’s Biggest Obstacle: Toxicity
Presenter: Oren Gilad, Ph.D., President and Chief Executive Officer

Presentation: Repli-Biom: a Novel Proteo-Genomic Approach to Identify Predictive Biomarkers of DDR Inhibitor Efficacy
Date & Time: Thursday, January 26, 2023 at 11:30 am ET
Session: Pondering Patient Selection: Improving Targeting Using Biomarkers & Screening Platforms
Presenter: Eric Brown, Ph.D., Scientific Consultant

Presentation: Adding On to Monotherapy: Combining DDR Inhibitors
Date & Time: Thursday, January 26, 2023 at 1:30 pm ET
Session: Conducting Combination Studies: A Two-Birds-One-Stone Approach to Tackling Toxicity & Resistance
Presenter: Oren Gilad, Ph.D., President and Chief Executive Officer